CN110691793A - 黏结蛋白聚糖-1（cd138）结合剂及其用 - Google Patents

黏结蛋白聚糖-1（cd138）结合剂及其用 Download PDF

Info

Publication number
CN110691793A
CN110691793A CN201880027031.2A CN201880027031A CN110691793A CN 110691793 A CN110691793 A CN 110691793A CN 201880027031 A CN201880027031 A CN 201880027031A CN 110691793 A CN110691793 A CN 110691793A
Authority
CN
China
Prior art keywords
binding agent
cdr
seq
syndecan
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880027031.2A
Other languages
English (en)
Chinese (zh)
Inventor
朱莉娅·科罗内拉
罗宾·理查森
安胡利·蒂默
罗兰·纽曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN110691793A publication Critical patent/CN110691793A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201880027031.2A 2017-04-26 2018-04-25 黏结蛋白聚糖-1（cd138）结合剂及其用 Pending CN110691793A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490463P 2017-04-26 2017-04-26
US62/490,463 2017-04-26
PCT/JP2018/016847 WO2018199176A1 (en) 2017-04-26 2018-04-25 Syndecan-1 (cd138) binding agents and uses thereof

Publications (1)

Publication Number Publication Date
CN110691793A true CN110691793A (zh) 2020-01-14

Family

ID=63918582

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027031.2A Pending CN110691793A (zh) 2017-04-26 2018-04-25 黏结蛋白聚糖-1（cd138）结合剂及其用

Country Status (5)

Country Link
US (1) US11242403B2 (https=)
EP (1) EP3615573A4 (https=)
JP (2) JP7254029B2 (https=)
CN (1) CN110691793A (https=)
WO (1) WO2018199176A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
AU2019353367A1 (en) * 2018-10-02 2021-02-18 Mitsubishi Tanabe Pharma Corporation Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
US20230272041A1 (en) 2020-04-22 2023-08-31 Dragonfly Therapeutics, Inc. Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
WO2023220542A1 (en) * 2022-05-10 2023-11-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Utilization of immortalized b cells to identify sdcbp as a novel therapeutic target in ovarian carcinoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945892A (zh) * 2007-12-26 2011-01-12 生物测试股份公司 用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
CN101952315A (zh) * 2007-12-26 2011-01-19 生物测试股份公司 靶向cd138的试剂及其应用
US20110123554A1 (en) * 2009-05-06 2011-05-26 Frank Osterroth Uses of immunoconjugates targeting cd138
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2014059442A2 (en) * 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
MX2020003783A (es) * 2017-10-02 2021-01-08 Visterra Inc Moleculas de anticuerpo de cd138 y sus usos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945892A (zh) * 2007-12-26 2011-01-12 生物测试股份公司 用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
CN101952315A (zh) * 2007-12-26 2011-01-19 生物测试股份公司 靶向cd138的试剂及其应用
US20110123554A1 (en) * 2009-05-06 2011-05-26 Frank Osterroth Uses of immunoconjugates targeting cd138
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PIERFRANCESCO TASSONE ET AL: "Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138 multiple myeloma cells", 《BLOOD》 *

Also Published As

Publication number Publication date
WO2018199176A1 (en) 2018-11-01
JP7254029B2 (ja) 2023-04-07
JP2023058488A (ja) 2023-04-25
US11242403B2 (en) 2022-02-08
EP3615573A4 (en) 2021-01-20
US20200181278A1 (en) 2020-06-11
JP2020517725A (ja) 2020-06-18
EP3615573A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
US20260102485A1 (en) Neutralizing anti-tl1a monoclonal antibodies
JP7254029B2 (ja) Ｓｙｎｄｅｃａｎ－１（ｃｄ１３８）結合剤およびその使用
JP6980075B2 (ja) がん細胞特異的な抗体、抗がん剤、及びがんの検査方法
CN109983030B (zh) cMET单克隆结合剂、其药物缀合物及其用途
BR112015014833B1 (pt) Anticorpo isolado ou fragmento de ligação, ácido nucleico, método in vitro, kit e composição de anticorpo
TW202302650A (zh) 針對dll3的結合分子及其應用
KR20160067846A (ko) Nav1.7 항체 및 그의 사용 방법
JP2021165268A (ja) シンデカン−１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質を含む医薬組成物
CN112153983B (zh) 抗ngly-1抗体及使用方法
WO2022152236A1 (zh) 抗trpv6单克隆抗体及其应用
WO2020071365A1 (en) Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor
JP2025082818A (ja) 遺伝子組換え抗体、それを含むキット、およびがん診断におけるその使用
BR122025019038A2 (pt) Anticorpo anti-tgfb2 isolado, imunoconjugado, formulação farmacêutica, usos de um anticorpo e de uma formulação farmacêutica, método in vitro de monitoramento da resposta ao tratamento e kit
BR112022018657B1 (pt) Anticorpos isolados anti-fator de crescimento transformador beta 3 (tgfb3), anticorpo anti-tgfb3, anticorpo anti-tgfb2/3, imunoconjugado, formulação farmacêutica, usos de um anticorpo, métodos in vitro para diagnosticar um indivíduo como tendo ssc e de monitoramento da resposta ao tratamento e kit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200114